The primary objective of the current study is to establish and validate for the first time a method to determine and quantify praziquantel (PZQ) and its main degradation products loaded in poly(methyl methacrylate–co-2-(diethylamino)ethyl methacrylate) P(MMA-co-DEAEMA) microparticles. A high-performance liquid chromatography (HPLC) approach was developed and validated in accordance with the United States Pharmacopeia (USP) guidelines, addressing parameters such as accuracy, linearity, solution stability, precision, specificity, robustness, sensitivity, and system suitability. The method employed a gradient mobile phase consisting of ultrapure water and acetonitrile, flowing at a rate of 1 mL/minute over a Phenomenex Kinetex® C18 column (5 µm, 100 Å, 250 × 4.6 mm) maintained at 35 °C. Detection was performed at the wavelength of 210 nm using a DAD/UV detector. Samples of the active pharmaceutical ingredient (API) praziquantel, microencapsulated praziquantel, placebo, and a mixture of related substances (A, B, and C) were prepared with 0.5% formic acid in water/ethanol, 45:55 v/v as the diluent, and injected at 20 °C. The method demonstrated a limit of quantification (LOQ) of 0.20 µg/mL for praziquantel and related substances. The method exhibited an excellent linear response, with all correlation coefficients (R2) values exceeding 0.998, which is well above the recommended specified limit of R2 > 0.995. Percent recoveries fell within the acceptable range of (95.0–105.0%), and all results indicated a percentage of relative standard deviation (%RSD) ≤ 2.0, indicating a robust methodology. Thus, the proposed HPLC technique proved to be selective, accurate, sensitive, and consistent in analyzing both the material content and its main degradation products.
Daher et al. (Fri,) studied this question.